Can eculizumab help prevent exacerbations of myasthenia gravis?

Apr 6, 2025 ... Eculizumab, a humanized anti-C5 monoclonal antibody, has been the standard of care for treating aHUS, and has been shown to be effective in ... Jul 22, 2024 ... FDA Approves Epysqli as Second Soliris Biosimilar ... The FDA approves Samsung Bioepis' Epysqli (eculizumab-aagh), marking the second US approval ... Jan 7, 2022 ... Soliris® (eculizumab) is the first medication to be approved by the Australian Therapeutic Goods Administration (TGA) for the treatment of an MS ... This medication helps to block the decrease in red blood cells and can improve the symptoms of anemia (such as tiredness, shortness of breath) and decrease the ... Mar 30, 2022 ... What Are Warnings and Precautions for Eculizumab? · Discontinue if being treated for serious meningococcal infection · Supplement dose with ... Sep 19, 2021 ... Eculizumab is an anti-C5 humanized monoclonal antibody that binds to C5, preventing its cleavage into C5a and C5b. Soliris was approved by the U.S. Food and Drug Administration in 2019 for the treatment of adults with NMOSD who are positive for anti-AQP4 antibodies. The ... Apr 3, 2025 ... Eculizumab (brand names Soliris, Bkemv, Epysqli) is used to treat paroxysmal nocturnal hemoglobinuria (PNH) in adults, and a rare chronic blood ... May 7, 2019 ... Treatment with eculizumab (Soliris, Alexion Pharmaceuticals) significantly reduces the risk for relapse among patients with AQP4-IgG ... Simple Search Results for: SolirisNew SearchNavigate to Advanced Search ; Biosimilar(s) · Epysqli · eculizumab-aagh ; Interchangeable(s) · Bkemv · eculizumab-aeeb.